

Product datasheet for TR306797

OriGene Technologies, Inc.

9620 Medical Center Drive, Ste 200 Rockville, MD 20850, US Phone: +1-888-267-4436 https://www.origene.com techsupport@origene.com EU: info-de@origene.com CN: techsupport@origene.cn

AGPAT1 Human shRNA Plasmid Kit (Locus ID 10554)

Product data:

Product Type: shRNA Plasmids

Product Name: AGPAT1 Human shRNA Plasmid Kit (Locus ID 10554)

Locus ID: 10554

Synonyms: 1-AGPAT1; G15; LPAAT-alpha; LPAATA

Vector: pRS (TR20003)

E. coli Selection: Ampicillin

Mammalian Cell Puromycin

Selection:

Format:

Retroviral plasmids

Components: AGPAT1 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID =

10554). 5µg purified plasmid DNA per construct

29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.

RefSeq: NM 006411, NM 032741, NM 032741.2, NM 032741.3, NM 032741.4, NM 006411.1,

NM 006411.2, NM 006411.3, BC003007, BC003007.1, BC090849, BC090849.1, BC002402,

BC004310, BC006818, BM763275, NM 032741.5, NM 006411.4

UniProt ID: Q99943

Summary: This gene encodes an enzyme that converts lysophosphatidic acid (LPA) into phosphatidic

acid (PA). LPA and PA are two phospholipids involved in signal transduction and in lipid biosynthesis in cells. This enzyme localizes to the endoplasmic reticulum. This gene is located in the class III region of the human major histocompatibility complex. Alternative splicing results in two transcript variants encoding the same protein. [provided by RefSeq, Jul 2008]

shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To

be certain that your variant of interest is targeted, please contact <u>techsupport@origene.com</u>. If you need a special design or shRNA sequence, please utilize our <u>custom shRNA service</u>.





Performance Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).